During the past decade, Kitasato University Hospital conducted 63 clinical trials. In the 10-year time frame, 63 clinical trials started and 21 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 23 clinical trials started and 11 clinical trials were completed. i.e. 47.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Kitasato University Hospital" #1 sponsor was "Hoffmann-La Roche" with 9 trials, followed by "Boehringer Ingelheim" with 7 trials sponsored, "Celgene" with 4 trials sponsored, "Eli Lilly and Company" with 3 trials sponsored and "Haruhiko Fukuda" with 3 trials sponsored. Other sponsors include 48 different institutions and companies that sponsored additional 41 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Kitasato University Hospital" #1 collaborator was "Ministry of Health, Labour and Welfare, Japan" with 4 trials as a collaborator, "Gilead Sciences" with 2 trials as a collaborator, "Japan Agency for Medical Research and Development" with 2 trials as a collaborator, "Japan Lung Cancer Society" with 2 trials as a collaborator and "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator. Other collaborators include 12 different institutions and companies that were collaborators in the rest 22 trials.

According to Clinical.Site data, the most researched conditions in "Kitasato University Hospital" are "Heart Failure" (5 trials), "Carcinoma, Non-Small-Cell Lung" (4 trials), "Coronary Artery Disease" (3 trials), "Crohn's Disease" (3 trials) and "Myelodysplastic Syndromes" (3 trials). Many other conditions were trialed in "Kitasato University Hospital" in a lesser frequency.

Most popular intervention types in "Kitasato University Hospital" are "Drug" (65 trials), "Device" (9 trials), "Biological" (4 trials), "Other" (3 trials) and "Procedure" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (18 trials), "Atezolizumab" (6 trials), "Bevacizumab" (4 trials), "Pembrolizumab" (4 trials) and "Enzalutamide" (3 trials). Other intervention names were less common.

The vast majority of trials in "Kitasato University Hospital" are 70 trials for "All" genders, 6 trials for "Male" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Kitasato University Hospital". undefined are not yet recruiting, 18 are recruiting, 23 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 29 completed trials in Kitasato University Hospital, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Kitasato University Hospital, 1 "Phase 1" clinical trials were conducted, 11 "Phase 2" clinical trials and 51 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 5 trials that are defined as “Not Applicable".